In collaboration with Swiss precision manufacturer CSEM, 3Brain AG has announced an exciting 3D microchip for their brain-on-chip portfolio. This first-in-class cell-electronic interface technology will allow scientists to study the complexity of 3D cellular networks at unrivalled scale and precision - and to gain novel mechanistic insights into the inner workings of the most complex structure in the universe: the human brain.

After months of experimentation in partnership with some world-class schools of medicine and top-tier diagnostic providers, the much-anticipated T-Cell Test from Hyris, based on innovative qPCR technology, is finally available for the European market with a CE-IVD mark. The new Test will change the way laboratories and diagnostic providers track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of the Hyris System™.

Collaboration provides an industry-leading offering for Life Sciences Companies

Integrated QC dashboard and unlimited validation cycles for interim and final datasets creates industry's most user-friendly validator

World-first as adaptive chemical space is launched as a service

Latest milestone brings the Selux Next-Generation Phenotyping (NGP) platform one step closer to impacting patient care with same-shift Antibiotic Susceptibility Testing (AST).

CaaMTech will help carry on Dr. Alexander Shulgin's legacy by developing ASRI's novel compounds

Funding from the NIH's National Institute on Drug Abuse (NIDA) will Support Further Development of ENA001, an Agnostic Respiratory Stimulant

Patients from Montgomery, Berks, and Chester Counties will now have access to clinical trials managed by Labcorp

Australian biotech Skin2Neuron Pty Ltd (S2N) has achieved what no one has to date - reversal of a dementia-like syndrome in a natural animal form of Alzheimer's disease.

This is the new fantasy creature from the Phantasticals campaign that Ferrer has relaunched, coinciding with Global Amyotrophic Lateral Sclerosis (ALS) Awareness Day, on June 21. The aim is to raise public awareness of this rare, neurodegenerative, progressive disease that affects the motor neurons in the brain. Ferrer is leading the ADORE Phase III clinical trial to evaluate the safety and efficacy of the investigational drug FNP122 in the treatment of ALS.

Globally recognized leader in international standards development joins the leader in digitalized clinical development.

A scientific paper recently published in Nature Biotechnology reveals new research regarding how we track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of Hyris System™. The study results from a joint effort of an international research team from the Icahn School of Medicine at Mount Sinai, Singapore Duke-NUS Medical School, laboratory diagnostic service providers Synlab, and Hyris.

Treatment in sight for over 25 million Americans after new clinical trial confirms safety and cognitive enhancement activity of low, once-a-day doses of Xanamem

ENA001, an Agnostic Respiratory Stimulant, Successfully Achieved the Study Primary Endpoint and Was Shown to Be Safe and Well Tolerated

Will use AI to identify and enroll the best candidates

Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the study results of Recardio's Phase 2 clinical study in Acute Myocardial Infarction will be presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in Madrid.

ENZYCHEM LIFESCIENCES' CHAIRMAN & CEO RECEIVES "TOP 100 INNOVATION CEO OF 2022 AWARD".

Wellgistics' Founder Brian Norton today announced the acquisition of Detroit-based Manufacturing and Distribution companies API and APD.